Duration of Action of 2 Insulin Glargine Products, LY2963016 and Lantus®, in Subjects with Type I Diabetes Mellitus (T1DM)

被引：0
|
作者：
Heise, Tim
Zhang, Xin
Lam, Eric Chen Quin
Seger, Mary E.
Coutant, David
Chua, Laiyi
Linnebjerg, Helle
机构：
来源：
DIABETES | 2014年 / 63卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
891-P
引用
收藏
页码：A228 / A228
页数：1
相关论文
共 50 条
  • [1] Duration of action of two insulin glargine products, LY2963016 insulin glargine and Lantus insulin glargine, in subjects with type 1 diabetes mellitus
    Linnebjerg, Helle
    Lam, Eric Chen Quin
    Zhang, Xin
    Seger, Mary E.
    Coutant, David
    Chua, Laiyi
    Kapitza, Christoph
    Heise, Tim
    DIABETES OBESITY & METABOLISM, 2017, 19 (01): : 33 - 39
  • [2] Comparison of duration of action of 2 insulin glargine products, LY2963016 and insulin glargine, in subjects with type 1 diabetes mellitus
    Linnebjerg, H.
    Heise, T.
    Zhang, X.
    Seger, M. E.
    Coutant, D.
    Chua, L.
    Lam, E.
    DIABETOLOGIA, 2014, 57 : S382 - S382
  • [3] Evaluation of Immunogenicity of LY2963016 Insulin Glargine Compared with Lantus® Insulin Glargine in Patients with T1DM or T2DM
    Deeg, Mark
    Ilag, Liza
    Huster, William J.
    Pollom, Robyn K.
    Zielonka, Jason
    Prince, Melvin J.
    Konrad, Robert J.
    DIABETES, 2014, 63 : A19 - A19
  • [4] Immunogenicity of LY2963016 insulin glargine and Lantus® insulin glargine in Chinese patients with type 1 or type 2 diabetes mellitus
    Wang, Weimin
    Song, Xiang
    Lou, Ying
    Du, Liying
    Zhu, Dalong
    Zhou, Zhiguang
    DIABETES OBESITY & METABOLISM, 2022, 24 (06): : 1094 - 1104
  • [5] Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus
    Ilag, L. L.
    Deeg, M. A.
    Costigan, T.
    Hollander, P.
    Blevins, T. C.
    Edelman, S. V.
    Konrad, R. J.
    Ortmann, R. A.
    Pollom, R. K.
    Huster, W. J.
    Zielonka, J. S.
    Prince, M. J.
    DIABETES OBESITY & METABOLISM, 2016, 18 (02): : 159 - 168
  • [6] Similar Efficacy and Safety with LY2963016 Insulin Glargine Compared with Lantus® Insulin Glargine in Patients with T1DM: The ELEMENT 1 Study
    Blevins, Thomas
    Dahl, Dominik
    Rosenstock, Julio
    Ilag, Liza
    Huster, William J.
    Pollom, Robyn K.
    Prince, Melvin J.
    DIABETES, 2014, 63 : A19 - A19
  • [7] LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes
    Lamb, Yvette N.
    Syed, Yahiya Y.
    BIODRUGS, 2018, 32 (01) : 91 - 98
  • [8] LY2963016 Insulin Glargine: A Review in Type 1 and 2 Diabetes
    Yvette N. Lamb
    Yahiya Y. Syed
    BioDrugs, 2018, 32 : 91 - 98
  • [9] COMPARATIVE PHARMACOKINETICS AND PHARMACODYNAMICS OF 2 INSULIN GLARGINE PRODUCTS, LY2963016 AND LANTUS®, IN HEALTHY SUBJECTS AT 2 DOSE LEVELS
    Zhang, X.
    Lam, E. C. Q.
    Seger, M.
    Coutant, D.
    Chua, L. Y.
    Tan, L. H.
    Soon, D.
    Linnebjerg, H.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2014, 106 : S264 - S264
  • [10] Evaluation of immunogenicity of LY2963016 insulin glargine compared with insulin glargine in patients with type 2 diabetes mellitus
    Ilag, L. L.
    Deeg, M. A.
    Huster, W. J.
    Costigan, T. M.
    Zielonka, J. S.
    Pollom, R. K.
    Prince, M. J.
    Konrad, R. J.
    DIABETOLOGIA, 2014, 57 : S397 - S398
12345